evipedia.ai
← Back

PEITC for Health & Longevity

Evidence Review created on 08/22/2026 using AI4L / Opus 5

Also known as: Phenethyl Isothiocyanate, 2-Phenethyl Isothiocyanate, Phenylethyl Isothiocyanate, β-Phenylethyl Isothiocyanate, Gluconasturtiin Hydrolysis Product, Watercress Isothiocyanate

Motivation

PEITC (phenethyl isothiocyanate) is the sharp-tasting sulfur compound that watercress and a few related cabbage-family plants release when their leaves are chewed or crushed. In the intact plant it sits inertly as a storage form, becoming active only when physical damage frees a plant enzyme. That chemistry is the source of the interest: a food constituent that behaves less like a nutrient and more like a drug.

Watercress has been grown and eaten for thousands of years and was prized in antiquity as a restorative green. Laboratory interest came much later, when animals fed the compound alongside a cancer-causing chemical from tobacco developed far fewer lung tumors than animals fed the chemical alone. That moved the compound out of the kitchen and into cancer-prevention research, where it has since been given to several hundred people under controlled conditions.

This review examines what is known about deliberately raising intake of this compound, whether from the vegetable or from a concentrate, in adults focused on long-term health. It sets out how it acts in the body, what human studies measured, the doses used, the safety findings that point the other way, and where the evidence is thin.

Benefits - Risks - Protocol - Conclusion

High-level overviews, expert commentary, and narrative reviews that explain what PEITC is and what its research program has produced.

No PEITC-specific or isothiocyanate-specific material was found on peterattiamd.com, hubermanlab.com, or lifespan.io. chriskresser.com carries a podcast episode and an article on sulforaphane, a different isothiocyanate, but nothing that addresses PEITC or watercress specifically, so it was not included in preference to more directly relevant sources.

Grokipedia

  • Phenethyl isothiocyanate

    A dedicated encyclopedic entry covering the compound’s chemistry, plant sources, hydrolysis from gluconasturtiin, metabolism, and the preclinical and clinical chemoprevention literature, with source citations throughout.

Examine

No Examine article exists for PEITC. The site’s supplement database does not currently cover this compound under any of its names.

PEITC is not a prescription drug, so the absence is not explained by Examine’s coverage policy for medications; it reflects the compound’s limited presence in the consumer supplement market.

ConsumerLab

No ConsumerLab article, product review, or clinical update exists for PEITC.

PEITC is not a prescription drug, so the absence is not explained by ConsumerLab’s coverage policy for medications; ConsumerLab tests product categories with meaningful retail volume, and no standalone PEITC category currently exists.

Systematic Reviews

The strongest pooled evidence touching PEITC comes from reviews of cruciferous vegetables and the isothiocyanate class rather than from reviews of the isolated compound.

Two of the five papers above address the claimed effect and two address principal risks, so both sides of the trade-off are represented. No systematic review or meta-analysis exists for the rodent bladder tumor-promotion signal described in the Potential Risks section; that literature consists of individual animal studies only.

Mechanism of Action

PEITC is stored in watercress as gluconasturtiin, an inert sugar-bound precursor. Damaging the plant releases myrosinase (the enzyme that cuts the sugar off), converting gluconasturtiin into PEITC. Gut bacteria do the same, less efficiently, when cooking has destroyed the plant enzyme.

The molecule’s reactive carbon atom binds covalently to cysteine residues on proteins. Two consequences dominate. First, it modifies KEAP1 (the sensor protein that normally holds the antioxidant switch inactive), releasing NRF2 (a transcription factor that switches on the cell’s own detoxification and antioxidant genes). This raises glutathione S-transferase activity, the enzyme family that tags foreign chemicals for excretion. Second, it inhibits several cytochrome P450 enzymes, notably CYP2A6, CYP2A13, and CYP2E1 (liver and lung enzymes that convert some inhaled chemicals into their DNA-damaging forms). PEITC therefore blocks activation and accelerates disposal simultaneously. It also activates HSF1, the switch controlling protective heat-shock proteins.

A competing account holds that anticancer effects in cell studies come not from NRF2 but the opposite: at high concentrations PEITC consumes intracellular glutathione and generates reactive oxygen species, selectively killing cells with already-elevated oxidative stress. Both accounts are supported experimentally; which dominates depends on dose.

Pharmacologically, PEITC is absorbed rapidly, is highly protein-bound, distributes widely with capacity-limited tissue uptake, is conjugated to glutathione by glutathione S-transferase and then converted to a mercapturic acid by N-acetyltransferase, and is cleared through the kidneys with a plasma half-life near five hours. It is carried by BCRP and MRP2 (pumps that push compounds back out of gut and kidney cells).

Historical Context & Evolution

Watercress (Nasturtium officinale) has been cultivated since antiquity and was used as food and as a folk remedy for scurvy, bronchial complaints, and general debility long before its chemistry was understood. The compound responsible for its pungency was not the original point: the plant was valued as a green vegetable.

The modern history begins in the 1980s, when synthetic isothiocyanates were screened as inhibitors of chemically induced tumors in rodents. Aromatic isothiocyanates, PEITC among them, blocked lung tumor formation induced by NNK (a cancer-causing chemical found only in tobacco) in rats and mice, and the effect was traced to inhibition of the enzymes that activate NNK rather than to any general antioxidant action. United States National Cancer Institute chemoprevention programs listed PEITC among candidate agents in the 1990s.

Translation to humans followed the biomarker route. Feeding studies gave smokers raw watercress and measured tobacco-carcinogen metabolites in urine; later trials gave the purified compound in oil and measured the same endpoints. Findings were positive but small, and concentrated in people lacking specific detoxification genes.

The picture complicated in the late 1990s and early 2000s when Japanese toxicology groups reported that dietary PEITC promoted bladder tumors in rats. Rather than treating this as settling the question in either direction, the field has held both results: the same reactivity that blocks carcinogen activation in the lung produces cytotoxicity and compensatory cell proliferation in the urinary tract, where the compound concentrates. Both findings are reproducible; the human relevance of the second remains untested.

Expected Benefits

Benefits below are framed for risk-aware adults who are willing to run a defined protocol, not for the average consumer. For this audience the relevant question is whether measurable biological change is achievable at tolerable doses, not whether population cancer rates would shift.

High 🟩 🟩 🟩

Increased Detoxification of Volatile Carcinogens and Toxicants

PEITC accelerates glutathione conjugation and urinary excretion of reactive volatile chemicals such as benzene, acrolein, acrylonitrile, and crotonaldehyde. Two independent randomized crossover trials support this, one with purified PEITC and one with a freeze-dried watercress drink, using the same urinary mercapturic acid endpoints. The effect is far larger in people who carry deletions of both the GSTM1 and GSTT1 genes (two glutathione S-transferase enzymes absent in a substantial minority of adults). A third trial on 1,3-butadiene was null overall and positive only in that subgroup.

Magnitude: With PEITC 10 mg four times daily for one week, benzene detoxification products rose 24.6% and acrolein products 15.1%; in double-null carriers benzene rose 95.4% (Yuan et al., 2016). A watercress drink supplying about 40 mg PEITC daily for two weeks raised acrolein products 65.6% and benzene products 37.3% in 188 completers (Hecht et al., 2025); the butadiene subgroup effect reached 90.0% (Boldry et al., 2020).

Medium 🟩 🟩

Reduced Metabolic Activation of the Tobacco Carcinogen NNK

PEITC inhibits the cytochrome P450 enzymes that convert NNK, a nitrosamine unique to tobacco, into the DNA-binding form that initiates lung tumors. This is the mechanism that produced the original rodent results, and it was confirmed in humans in a single randomized crossover trial in 82 smokers using deuterium-labeled NNK, which isolates the metabolic ratio from variation in exposure. The effect was statistically significant but small, and no trial has tested whether it translates into fewer tumors.

Magnitude: The urinary NNK metabolic activation ratio fell 7.7% during PEITC treatment relative to placebo (P = 0.023) in 82 smokers taking 10 mg four times daily for one week (Yuan et al., 2016).

Lower Oxidative DNA Damage in Circulating White Blood Cells

Raw watercress, the principal dietary source of PEITC, reduced strand breaks and oxidized purine bases in lymphocytes in a randomized crossover study of 60 adults over eight weeks. The design cannot separate PEITC from the carotenoids and other constituents that also rose, and the benefit was concentrated in smokers, who start with more damage. It is nonetheless the only human evidence that isothiocyanate-rich intake alters a genotoxicity endpoint rather than an excretion endpoint.

Magnitude: 85 g raw watercress daily for eight weeks reduced basal lymphocyte DNA damage by 17% (P = 0.03) and basal plus oxidative purine damage by 23.9% (P = 0.002), with larger changes in smokers (Gill et al., 2007).

Disease Stabilization and Quality of Life in Advanced Oral Cancer

In a blinded, placebo-controlled randomized trial, 72 patients with advanced oral or oropharyngeal cancer received a texture-modified nutritional jelly with or without added PEITC alongside standard care. The PEITC arm showed longer progression-free survival, more stable disease, better quality-of-life scores, and higher serum p53, the tumor-suppressor protein the intervention was designed to reactivate. No serious intervention-related adverse events occurred. This is a single trial in a specific advanced-disease population and does not generalize to prevention in healthy adults.

Magnitude: 20 mg PEITC in 200 g of jelly, five days weekly for twelve weeks, produced significantly longer progression-free survival than placebo (P < 0.05) and a higher proportion of patients with improved quality of life, stable disease, and raised serum p53 (P < 0.001) (Lam-Ubol et al., 2023).

Low 🟩

Increased Excretion of Heterocyclic Amines From Grilled Meat

A randomized crossover placebo-controlled trial paired grilled beef with a PEITC-rich vegetable sauce or placebo and measured urinary metabolites of PhIP and MeIQx (two cancer-causing chemicals formed when meat is charred). Excretion rose significantly. The evidence is one small single-meal trial, so durability is unknown.

Magnitude: In 21 healthy adults, 100 g of the PEITC-rich sauce eaten with grilled beef raised urinary PhIP and MeIQx glucuronide metabolites significantly (P < 0.0001), while 50 g raised only MeIQx metabolites (P < 0.05); the trial reports no percentage change (Kaewsit et al., 2021).

Lower Cancer Incidence Associated With Dietary Isothiocyanate Exposure

Pooled observational data link higher cruciferous intake to modestly lower risk of several cancers, with the association strongest in people lacking glutathione S-transferase genes. The exposure measured is whole vegetables, not PEITC, and residual confounding by overall diet quality is unresolved.

Magnitude: Pooled across 226 studies, higher cruciferous intake carried an odds ratio of 0.77 and a risk ratio of 0.96 for cancer overall, with thresholds near 5.4 servings weekly for lung and colorectal cancer (Zheng et al., 2025).

Systemic Anti-Inflammatory and Antioxidant Signaling ⚠️ Conflicted

Cell and rodent work shows PEITC suppresses NF-κB (a master inflammation switch) and raises antioxidant enzyme output through NRF2. The one human trial that measured systemic markers found nothing, which is the central conflict: mechanism is well established, systemic human effect is not.

Magnitude: PEITC 40 mg daily for one week produced no change in urinary 8-iso-prostaglandin F2α, a marker of oxidative stress, or in prostaglandin E2 metabolite, a marker of inflammation, in 82 smokers (Yuan et al., 2016).

Speculative 🟨

Improved Glucose Handling and Reduced Fat Accumulation

PEITC stimulates glucose uptake in cultured muscle cells, blocks fat accumulation in adipocytes via KEAP1, and activates leptin signaling in mice. No human study has measured a metabolic endpoint; the basis is mechanistic and animal.

Suppression of Gut and Oral Pathogens

PEITC impairs bacterial virulence in culture, including Vibrio cholerae, and alters the gut microbiome in mice. No human trial has tested antimicrobial or microbiome endpoints, so the basis is entirely in vitro and rodent work.

Rodent models of amyloid-induced brain injury report that PEITC dampens inflammatory signaling and restores redox balance. No human data of any kind exist; the basis is isolated animal reports.

Benefit-Modifying Factors

  • GSTM1 and GSTT1 deletion status: Adults carrying null variants of both genes, which encode two glutathione S-transferase enzymes, showed roughly four times the detoxification response of gene-positive adults in the human trials. Carriers of both genes showed no measurable benefit at all.

  • Baseline carcinogen and toxicant exposure: The measured benefits are proportional to what there is to detoxify. Smokers, people with occupational solvent exposure, and those in wildfire or high-pollution settings showed larger changes than unexposed adults, in whom the endpoints barely move.

  • Baseline oxidative DNA damage: In the watercress trial, participants who began with more lymphocyte DNA damage, mainly smokers, improved substantially more than those who began near the low end of the range.

  • Sex: No sex-specific difference in detoxification response has been reported; the trials enrolled both sexes without stratified findings. The lung-cancer epidemiology is strongest in women who never smoked, but this reflects the cohorts studied rather than a demonstrated sex effect.

  • Age and older adults: No trial has stratified by age, and enrollment has skewed to middle age. Older adults with reduced kidney function clear the mercapturic acid metabolite more slowly, which raises exposure per dose but has not been shown to change benefit.

  • Gut myrosinase capacity: When the plant enzyme is destroyed by cooking, conversion depends on gut bacteria and varies several-fold between individuals, so identical vegetable intake produces markedly different circulating PEITC.

  • Pre-existing conditions: Active cancer changes the calculus, since the only trial with a clinical rather than biochemical endpoint was in advanced oral cancer. Chronic kidney disease, by slowing clearance, and inflammatory bowel disease, by altering gut flora, both plausibly shift response.

Potential Risks & Side Effects

Risks are framed for adults deliberately taking concentrated PEITC or large habitual watercress servings, not for people eating an ordinary mixed diet.

High 🟥 🟥 🟥

Altered Metabolism of Co-Administered Drugs

PEITC and the cruciferous diet that supplies it inhibit some cytochrome P450 enzymes while inducing others, so drug exposure can move in either direction depending on the drug. Human crossover studies using probe drugs demonstrate this directly, and a meta-analysis of dietary intervention trials quantifies it at the diet level. The clinical consequence is unpredictable rather than uniformly harmful: exposure to a narrow-therapeutic-index drug may rise or fall enough to matter without any symptom to signal it.

Magnitude: A single 50 g watercress dose raised chlorzoxazone exposure 56% and prolonged its half-life 53% (Leclercq et al., 1998) and cut the oxidative metabolite of acetaminophen 28% (Chen et al., 1996). Pooled cruciferous intervention trials show CYP1A2 (a liver enzyme handling caffeine and several psychiatric drugs) activity rising 20–40% (Eagles et al., 2020).

Medium 🟥 🟥

Bladder and Liver Tumor Promotion in Rodents ⚠️ Conflicted

Dietary PEITC damages rat bladder lining, and the resulting repair proliferation promotes tumors. Rats given 0.1% dietary PEITC developed papillary or nodular hyperplasia universally, with papillomas and carcinomas in some animals even without a chemical initiator, and PEITC also modestly increased large liver foci. The conflict is direct: the same compound and the same reactivity inhibit lung carcinogenesis in the same species. The mechanism is cytotoxicity from urinary concentration, so it is dose-dependent and plausibly avoidable, but no human study has looked for it.

Magnitude: 0.1% dietary PEITC for 32 weeks produced papillary or nodular bladder hyperplasia in 100% of uninitiated F344 rats and significantly raised carcinoma incidence after initiation (Hirose et al., 1998); acute epithelial erosion, hemorrhage, and inflammation peaked within two to three days of starting the diet (Akagi et al., 2003).

Low 🟥

Gastrointestinal Irritation and Poor Tolerability

PEITC is a volatile, chemically reactive compound that stimulates irritant nerve endings, producing burning, nausea, and reflux. Every human trial therefore delivered it in olive oil, a jelly, or a flavored drink rather than neat. The evidence is trial tolerability and dropout data; the effect reverses on stopping.

Magnitude: Irritation increases with the concentration of free PEITC reaching mucosa and is reduced by a fat or gel matrix and by dosing with food; the trials report no incidence figure for irritation, only that 188 of 240 enrolled participants completed the two-week watercress-drink protocol (Hecht et al., 2025).

Glutathione Depletion and Pro-Oxidant Stress at High Doses

Above roughly 10 µmol/L in culture, PEITC consumes intracellular glutathione faster than it is resynthesized and generates reactive oxygen species in normal as well as malignant cells. The evidence is cell work only, and it does not resolve how much of the resulting toxicity glutathione status actually governs.

Magnitude: Cytotoxicity rises with concentration and is not confined to malignant cells: in cultured rat esophageal cells PEITC was significantly more toxic than its longer-chain homolog in both tumorigenic and non-tumorigenic lines, while pre-depleting glutathione did not augment that toxicity (Hudson et al., 2005); no human trial has measured tissue glutathione at supplemental doses, so the literature gives no in vivo figure.

Thyroid Effects Where Iodine Is Insufficient

Isothiocyanates and related breakdown products compete with iodide uptake by the thyroid. Pooled human data show no overall association with thyroid cancer, but a positive one where iodine intake is low.

Magnitude: In iodine-deficient regions, high cruciferous intake carried a relative risk of 1.43 for thyroid cancer (95% confidence interval 1.18–1.74), with no association overall (Cho & Kim, 2015).

Speculative 🟨

Blunting of Treatments That Depend on Oxidative Stress

NRF2 activation protects tumor cells as readily as healthy ones, so concurrent use during radiotherapy or oxidative chemotherapy could theoretically reduce efficacy. No clinical study has tested this; the concern is mechanistic.

Reduced Exposure to Drugs Handled by Cellular Efflux Pumps

PEITC is transported by and inhibits BCRP and MRP2, pumps that move many drugs across gut and kidney membranes. Interaction is plausible from transport studies in cells, but no human interaction study exists.

Skin Sensitization From Concentrated Material

Concentrated PEITC acted as a contact sensitizer in mice, and handling neat material can irritate skin and eyes. No human case series exists, so the basis is a single animal study plus general reactivity.

Risk-Modifying Factors

  • GSTM1, GSTT1, and GSTP1 status: These three glutathione S-transferase genes govern conjugation and clearance. The deletions that magnify benefit also raise free PEITC per dose, so gene-null adults get more effect and, plausibly, more mucosal irritation.

  • NAT2 acetylator phenotype: N-acetyltransferase 2 converts the glutathione conjugate into the excreted mercapturic acid. Slow acetylators accumulate the intermediate, which is itself biologically active in the urinary tract.

  • Baseline thyroid biomarkers and iodine status: Low urinary iodine or a thyroid-stimulating hormone already at the high end of range converts a theoretical goitrogenic concern into a plausible one, since competition for iodide uptake matters most when iodide is scarce.

  • Baseline kidney function and urine concentration: PEITC metabolites concentrate in urine. Reduced kidney function, low fluid intake, and urinary retention all raise bladder-wall exposure, which is the mechanism behind the rodent finding.

  • Sex: No sex difference in adverse effects has been demonstrated in the human trials, which enrolled both sexes. Bladder cancer incidence is substantially higher in men, so any bladder-related concern carries a higher baseline in men.

  • Pre-existing conditions: Prior bladder cancer, interstitial cystitis (chronic bladder inflammation), recurrent urinary infection, hypothyroidism, iodine deficiency, gastro-esophageal reflux, and inflammatory bowel disease each amplify a specific listed risk. Anticoagulation matters through watercress vitamin K rather than PEITC itself.

  • Age and older adults: Older adults concentrate urine more, clear metabolites more slowly, take more interacting medications, and have higher baseline bladder cancer risk, so every listed risk is larger at the older end of the target range.

Key Interactions & Contraindications

  • Warfarin and vitamin K antagonists: Caution; watercress is vitamin-K-rich, so large or variable servings destabilize the international normalized ratio and risk either clotting or bleeding. Constant intake with monitoring is the mitigation; purified PEITC contains no vitamin K.

  • CYP1A2 substrates (theophylline, clozapine, olanzapine, tizanidine, caffeine): Monitor; cruciferous-enriched intake induces this enzyme 20–40%, lowering drug levels and potentially causing loss of effect. Dose separation and level rechecks after any sustained change in intake are the mitigation.

  • CYP2E1 substrates (acetaminophen, chlorzoxazone, isoniazid, ethanol): Caution; PEITC inhibits this enzyme, cutting formation of the toxic acetaminophen metabolite but raising exposure to chlorzoxazone. Effect direction is drug-specific, so review each agent individually.

  • Narrow-therapeutic-index agents (cyclosporine, tacrolimus, phenytoin, digoxin, lithium): Caution; small metabolic or transporter shifts translate into clinically meaningful level changes. Stable intake with drug-level checks four weeks after starting or stopping is the mitigation.

  • Oxidative chemotherapy and radiotherapy (platinum agents, anthracyclines, external-beam radiotherapy): Absolute contraindication outside oncologist supervision; NRF2 activation may protect tumor cells and reduce treatment efficacy. Timing separation is not established, so use only within a trial or with specialist approval.

  • Antithyroid drugs (methimazole, propylthiouracil) and levothyroxine: Monitor; added competition for iodide uptake can shift thyroid hormone output, requiring dose review. Thyroid-stimulating hormone and free thyroxine eight weeks after any sustained intake change detect the shift.

  • Over-the-counter acetaminophen: Monitor rather than avoid; watercress reduced the oxidative metabolite by 28% in humans, which is protective at ordinary doses but has not been studied in overdose or in heavy alcohol use.

  • Over-the-counter proton-pump inhibitors and antacids: Caution; raising gastric pH alters isothiocyanate stability and gut bacterial conversion of the precursor, changing how much PEITC is actually generated from vegetable sources.

  • N-acetylcysteine, glutathione, and high-dose antioxidant supplements: Caution; these directly quench the electrophilic reactivity PEITC depends on and can neutralize its effect. Separation by at least four hours is the usual mitigation when both are used.

  • Sulforaphane, broccoli sprout extract, and other isothiocyanate supplements: Additive; they act on the identical NRF2 pathway, so combined use compounds both the intended induction and the mucosal irritation. Total isothiocyanate load, not the individual product, is the quantity that matters.

  • Iodine and kelp supplements: Additive in the protective direction; adequate iodine offsets the competitive uptake concern. Pairing is reasonable where dietary iodine is uncertain.

  • Milk thistle, curcumin, resveratrol, and other NRF2-activating botanicals: Additive; concurrent use amplifies NRF2 signaling beyond what any single agent was studied at, with unknown consequences for tumor-cell protection.

Populations who should avoid PEITC:

  • Adults with a personal history of bladder cancer or non-muscle-invasive bladder cancer under surveillance, given the rodent promotion signal and the absence of human safety data
  • Adults with active interstitial cystitis, recurrent hematuria (blood in the urine), or chronic urinary retention
  • Adults undergoing active oxidative chemotherapy or radiotherapy, except within a supervised trial
  • Adults with untreated hypothyroidism or documented iodine deficiency (urinary iodine below 100 µg/L)
  • Adults with chronic kidney disease at stage 4 or worse (estimated glomerular filtration rate below 30 mL/min/1.73 m²)
  • Adults with decompensated liver disease (Child-Pugh Class C) or transaminases above three times the upper limit of normal
  • Pregnant and breastfeeding women, for whom no safety data at supplemental doses exist
  • Children and adolescents under 18, who were excluded from every trial

Risk Mitigation Strategies

  • Whole-food form in preference to the isolate: Whole-food matrices delivered the largest detoxification effects at equivalent PEITC content while diluting peak concentration, which lowers the mucosal irritation and urinary-concentration risks driving the rodent bladder finding.

  • Daily intake capped at the trial dose: Human trials used 40 mg daily and no more. Remaining at or below that level avoids the exposure range where glutathione depletion and pro-oxidant stress appear in cell work.

  • Divided dosing with food and fat: Four 10 mg doses in oil, as the trials used, blunt peak concentration and reduce the burning and nausea caused by irritant-receptor stimulation.

  • High fluid intake and absence of urinary stasis: Two liters of fluid daily and prompt voiding dilute bladder-wall exposure to concentrated metabolites, the direct mechanism behind rodent bladder toxicity.

  • Cyclical rather than continuous use: Rodent bladder lesions regressed once exposure stopped. Six to eight weeks on with four weeks off limits cumulative urothelial exposure while preserving enzyme induction.

  • Thyroid and iodine testing before and during use: Confirmed iodine sufficiency removes the only condition under which the pooled thyroid cancer association appeared, and an eight-week recheck of thyroid-stimulating hormone catches drift.

  • Medication review before starting: Screening for CYP1A2 substrates, CYP2E1 substrates, warfarin, and narrow-therapeutic-index agents prevents the silent exposure changes that are this compound’s most likely real-world harm.

  • Constant rather than fluctuating intake: Steady intake prevents the swings in drug-metabolizing enzyme activity that destabilize anticoagulation and narrow-index drug levels far more than a consistently high intake would.

  • Urological evaluation of visible blood in urine: Hematuria is the earliest human-detectable analog of the rodent urothelial injury, and it calls for investigation rather than for dose reduction.

Therapeutic Protocol

  • Standard investigational dose: 40 mg daily of purified PEITC, as 10 mg in 1 mL olive oil four times daily. This is the regimen Hecht and Hatsukami at Minnesota and Yuan at Pittsburgh used across all three smoker trials.

  • Whole-food alternative: A freeze-dried watercress drink supplying roughly 40 mg PEITC daily in three divided doses, developed by the same Minnesota group, produced larger detoxification effects than the purified compound and is the approach El-Bayoumy and Stoner argue for.

  • Culinary alternative: 85 g raw watercress daily, the dose used in the Ulster DNA-damage trial, or roughly two cups of loosely packed leaves. Watercress must be raw or briefly wilted; boiling destroys the converting enzyme.

  • Oncology-adjunct approach: 20 mg PEITC in a texture-modified nutritional jelly, five days weekly, developed by Trachootham’s group at Mahidol University for advanced oral cancer. Used alongside standard care, never instead of it.

  • Competing approaches: Purified-compound and whole-food strategies are genuinely unresolved. The purified route allows exact dosing; the whole-food route delivers additional isothiocyanates and produced larger effects. Neither has been shown superior head to head.

  • Best time of day: No circadian data exist. Trials dosed with meals across the waking day; morning-to-evening spacing keeps the pungent dose away from bedtime and reduces nocturnal reflux.

  • Half-life: Plasma half-life is about 4.9 hours after 100 g of watercress, with peak concentration near 928 nmol/L at 2.6 hours. This short exposure window is the reason trials dosed repeatedly.

  • Single versus split dosing: Split dosing is standard. Every human trial used three or four daily doses, which sustains exposure across the short half-life and avoids the peak concentrations linked to mucosal irritation.

  • Genetic polymorphisms: GSTM1 and GSTT1 null status is the dominant modifier and can be read from most consumer genotyping panels. Double-null individuals may achieve trial-level effects at lower doses; gene-positive individuals may see nothing at 40 mg.

  • Sex-based differences: No sex-specific dosing has been established. Trials enrolled men and women at similar doses without reporting differential response, so no adjustment is currently justified.

  • Age considerations: No age-adjusted dosing exists. For adults over 70, reduced kidney clearance and higher baseline bladder cancer risk argue for the whole-food route and the lower end of intake rather than purified 40 mg.

  • Baseline biomarkers: Thyroid-stimulating hormone, urinary iodine, kidney function, and a baseline urinalysis determine whether the protocol is appropriate at all, and urinary mercapturic acids confirm that the compound is being generated and excreted.

  • Pre-existing conditions: Active reflux argues for the jelly or drink matrix over oil capsules; reduced kidney function argues for lower intake; prior bladder disease argues against the protocol entirely.

Discontinuation & Cycling

  • Not a lifelong commitment: No trial ran longer than twelve weeks, and no long-term human safety data exist. Treating PEITC as an indefinite daily supplement extends far beyond anything that has been studied.

  • Exposure-linked, not habit-forming: The measured benefits track current exposure to carcinogens and disappear when dosing stops. There is no accumulation and no reason to continue when the exposure that motivated use has ended.

  • No withdrawal effects: None have been reported in any trial. Enzyme induction reverses over days to weeks as NRF2 signaling returns to baseline, without rebound symptoms.

  • No tapering required: Because there is no dependence and no rebound, stopping abruptly is acceptable. Trials used one-week washout periods between arms with no reported difficulty.

  • Cycling is prudent rather than proven: Cycling has not been tested for efficacy. It is suggested because rat urothelial lesions regressed after exposure stopped, making intermittent use a reasonable hedge against cumulative bladder exposure.

  • A workable cycle: Six to eight weeks on followed by four weeks off, or dosing only during defined exposure periods such as wildfire smoke, travel to polluted regions, or occupational solvent work.

Sourcing and Quality

  • Freeze-dried whole watercress: The best-evidenced concentrate. It preserves gluconasturtiin, the plant enzyme, and companion isothiocyanates, and it is the material used in the largest human trial. Some products state PEITC content per serving.

  • Purified synthetic PEITC: Chemically identical to the natural compound and available from research chemical suppliers, but rarely sold as a finished consumer supplement. Trials used pharmaceutical-grade material prepared under an investigational drug application.

  • Stated compound content: Labels often say “cruciferous complex” or “watercress extract” without stating isothiocyanate content. A milligram amount of PEITC or gluconasturtiin per dose, quantified by chromatography, is what makes a product verifiable.

  • Third-party testing: PEITC has no compendial monograph, so certification is limited. NSF, USP, or Informed Choice facility certification plus a batch certificate of analysis covering identity, potency, heavy metals, and microbial limits is the available standard.

  • Stability and storage: PEITC is volatile and degrades with heat, light, and moisture. Oil-suspended softgels and sealed sachets hold potency better than loose powder, refrigeration slows loss, and a weakened pungent odor signals degradation.

  • Watercress source safety: Wild-gathered watercress from slow water can carry liver fluke and bacterial contamination. Cultivated, hydroponically grown, or commercially washed product avoids this exposure; foraged leaves do not.

  • Commercial interest: Most consumer guidance on cruciferous concentrates, including Life Extension’s, is published by companies selling those concentrates. Their recommendation to supplement rather than eat the vegetable is not a neutral reading of the evidence.

Practical Considerations

  • Time to effect: Detoxification endpoints shift within one to two weeks, the shortest dosing period tested. DNA-damage endpoints took eight weeks. Clinical endpoints have only been measured over twelve weeks, in one trial.

  • Nothing to feel: The effects are biochemical and invisible. Anyone expecting a subjective change will conclude the protocol is not working; confirmation requires urinary metabolite testing or none at all.

  • Cooking destroys the pathway: Boiling watercress for three minutes abolishes the converting enzyme, leaving conversion entirely to gut bacteria, which varies severalfold between individuals. Raw leaves, or leaves added after cooking, retain it.

  • Ignoring the genotype: Adults carrying both glutathione S-transferase genes showed no measurable detoxification benefit in the human trials. Running the protocol without checking GSTM1 and GSTT1 status risks doing nothing at all.

  • Regulatory status: PEITC is not an approved drug anywhere. In the United States it is sold, when sold at all, as a dietary supplement ingredient, and its clinical use has been confined to investigational new drug applications.

  • Cost and accessibility: Watercress is inexpensive and widely available. Standalone PEITC products are scarce and cost far more per dose, which is a poor trade given that the whole-food form performed at least as well.

  • No payer involvement: Both watercress and any concentrate are self-funded consumer purchases with no insurer or national health system reimbursement on either side, so no institutional financial incentive favors one route over the other.

Interaction with Foundational Habits

  • Sleep: Indirect and mildly negative if mistimed. PEITC has no known effect on sleep architecture, but its pungency stimulates irritant receptors and can provoke reflux; taking the final dose at least three hours before bed avoids the only plausible sleep disruption.

  • Nutrition: Direct and potentiating. Fat improves absorption of this lipophilic compound, so dosing with a meal containing oil raises exposure. Adequate iodine from seafood, dairy, or iodized salt offsets the competitive uptake concern. Antioxidant supplements taken simultaneously quench the reactivity the compound depends on.

  • Exercise: Indirect and possibly blunting at high doses. Exercise adaptation depends partly on transient oxidative stress, and strong NRF2 activation could theoretically dampen that signal, as has been debated for antioxidants generally. No study has tested PEITC around training; dosing away from sessions is a cautious default.

  • Stress management: Indirect and potentiating. PEITC activates HSF1, the heat-shock response that sauna, cold exposure, and exercise also engage, so these practices work on an overlapping pathway. No human study has measured cortisol or subjective stress with PEITC.

Monitoring Protocol & Defining Success

Baseline testing establishes whether the protocol can work and whether it is safe to run. Genotyping for GSTM1 and GSTT1 determines the expected magnitude of response, since gene-positive adults showed no detoxification benefit in the trials. A baseline urinalysis, kidney panel, liver panel, thyroid-stimulating hormone, and free thyroxine screen for the three conditions that turn theoretical risks into real ones: urothelial disease, impaired clearance, and thyroid vulnerability. Urinary iodine is worth adding where dietary iodine is uncertain.

Ongoing monitoring is light because the intervention is short. Thyroid-stimulating hormone, free thyroxine, and urinalysis are repeated at eight weeks, then at the end of each cycle or every six months where use continues. Levels of narrow-index medications are rechecked four weeks after starting and four weeks after stopping, because enzyme activity moves in both directions.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
GSTM1 / GSTT1 genotype Null for both predicts strongest response Determines whether the protocol will do anything GST = glutathione S-transferase, the enzyme family that tags toxins for excretion. One-time test; available on most consumer panels
TSH 0.5–2.0 mIU/L Detects thyroid suppression from iodide competition TSH = thyroid-stimulating hormone. Conventional range extends to 4.5 mIU/L; functional practitioners use the tighter band. Morning, fasting draw
Free T4 1.0–1.5 ng/dL Confirms actual hormone output when TSH drifts T4 = thyroxine, the main thyroid hormone. Interpreted alongside TSH, never alone
Urinary iodine 100–200 µg/L Identifies the deficiency state in which the thyroid risk appears Spot urine varies day to day, so a repeat is warranted before acting on a low result
Urinalysis with microscopy No blood, no casts, specific gravity below 1.020 Earliest detectable analog of the rodent bladder injury Any visible or microscopic blood requires urological evaluation, not dose reduction. Clean midstream sample
eGFR and serum creatinine eGFR above 90 mL/min/1.73 m² Clearance determines urinary metabolite concentration eGFR = estimated glomerular filtration rate, a measure of kidney filtering capacity. Fasting not required; heavy protein intake or intense exercise beforehand distorts the result
ALT and AST Below 25 U/L (men), below 20 U/L (women) Screens for the liver signal seen in rodent promotion studies ALT and AST = liver enzymes released when liver cells are stressed. Conventional upper limits near 40 U/L are far looser. Fasting preferred
Urinary mercapturic acids of acrolein and benzene No established target; track change from the individual’s own baseline Confirms the compound is being generated and is working Specialist assay, available mainly through research laboratories. First-morning void, before and after two weeks of dosing
INR (if anticoagulated) Within the individually prescribed target Detects destabilization from vitamin K in watercress INR = international normalized ratio, a measure of blood clotting speed. Applies to the vegetable, not to purified PEITC
hs-CRP Below 1.0 mg/L Tracks the systemic inflammation endpoint the one human trial failed to move hs-CRP = high-sensitivity C-reactive protein. Invalid within two weeks of any infection or hard training block

Qualitative markers worth tracking alongside the laboratory values:

  • Tolerability: burning, nausea, reflux, or an unpleasant aftertaste severe enough to threaten adherence
  • Urinary symptoms: urgency, frequency, discomfort on voiding, or any change in urine color
  • Energy and cognitive clarity: no effect is expected, so a change in either direction is worth investigating rather than attributing to the protocol
  • Adherence: whether four daily doses are actually being taken, since the trials’ effects depend on sustained exposure across a short half-life
  • Thyroid symptoms: cold intolerance, unusual fatigue, or hair thinning, which would suggest thyroid drift before it appears in bloodwork

Emerging Research

Research directions below matter to adults who would run this protocol themselves, not to population screening programs. The open questions are whether whole-food delivery beats the isolated compound, whether genotype-targeted dosing works, and whether the rodent bladder signal exists in humans.

  • CRUCIAL-R randomized trial in bladder cancer: NCT07391137, 250 patients, randomized, primary endpoint recurrence-free survival at one year with high cruciferous intake after standard immunotherapy. It also measures urinary isothiocyanate levels, making it the first trial to link intake, urinary exposure, and bladder outcome directly.

  • Watercress detoxification trial reported: NCT03978117, phase 2, 300 enrolled at two sites, comparing a freeze-dried watercress drink against maltodextrin placebo. Results published in 2025 showed six of seven toxicant detoxification products rising significantly (Hecht et al., 2025), shifting the field toward whole-food delivery.

  • Oral cancer jelly program: NCT03034603, 96 patients, endpoints adverse events, quality of life, tumor response, and progression-free survival. The published analysis is the only trial reporting a clinical rather than biochemical endpoint (Lam-Ubol et al., 2023).

  • Watercress in cancer survivors, status unresolved: NCT02468882, phase 3, 200 participants, endpoints including DNA damage, treatment toxicity, and quality of life. Registry status is listed as unknown with no results posted, so its findings cannot currently be assessed.

  • Withdrawn lymphoproliferative trial: NCT00968461, a phase 1 study of PEITC in leukemia and lymphoproliferative disorders at MD Anderson, was withdrawn with zero enrollment. Its cancellation is itself informative about how difficult the compound has been to develop as a therapeutic.

  • Genotype-stratified dosing: The largest open question. Effects were four to five times larger in adults null for both glutathione S-transferase genes (Yuan et al., 2016). No trial has yet prospectively enrolled by genotype, which would be the fastest route to a definitive result.

  • Human bladder safety, unstudied: Rodent work shows consistent urothelial toxicity and tumor promotion (Hirose et al., 1998). No human study has examined urothelial cells during PEITC dosing, and a finding of injury would weaken the case for supplementation substantially.

  • Dose ceiling and the pro-oxidant threshold: Work on PEITC as a dual NRF2 and HSF1 activator argues that protection and cytotoxicity are separated only by concentration (Dayalan Naidu et al., 2018). Defining the human threshold would determine whether doses above 40 mg are ever justifiable.

Conclusion

PEITC is a reactive sulfur compound released from watercress and a few related vegetables. It works by two complementary routes: it blocks the liver and lung enzymes that turn certain inhaled chemicals into forms that damage genetic material, and it switches on the cell’s own machinery for tagging those chemicals and flushing them out. That combination is unusual and well demonstrated in people.

The human evidence is real but narrow. Randomized trials in smokers and healthy adults show that a defined daily amount, taken in divided doses for one to two weeks, measurably increases the excretion of several harmful volatile chemicals, and the effect is several times larger in the substantial minority of adults who lack two specific detoxification genes. A separate trial found less damage to the genetic material in white blood cells after eating the raw vegetable, and one trial in advanced mouth cancer found longer time before the disease worsened. Beyond these, the record thins quickly into cell and animal work.

The counterweight is specific rather than vague. In rats, the same reactivity that protects the lung irritates the bladder lining and promotes tumors there, an effect that has been reproduced repeatedly and never looked for in humans. The compound also shifts how the body handles several common medicines, in both directions.

Evidence quality is moderate and unusually clean: the trials were publicly funded and independent, with commercial interest confined to the supplement companies that promote concentrates rather than the vegetable. Much remains genuinely unsettled.

Top - Benefits - Risks - Protocol